Angelman Syndrome patients and families lack effective FDA-approved treatment options despite years of waiting

Families with children diagnosed with Angelman syndrome face a devastating reality: there are zero FDA-approved therapies to treat this rare genetic neurological disorder, leaving them dependent on experimental clinical trials with uncertain outcomes. When promising drug candidates like Ultragenyx's apazunersen fail in late-stage trials, patients lose years of hope and must restart the agonizing search for viable treatment options, while the disease continues to progress unchecked.